Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $336.08M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.18M
Average 0.09M
Income Statement
Follow revenue through to earnings.
Revenue
$36,000.00
FY 2025 · Annual
-41.0% YoYOperating Income
-$203.77M
FY 2025 · Annual
Net Income
-$274.45M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.65M | 84.68M | 130K | 61K | 36K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.54M |
| Gross Profit | 10.65M | 84.68M | 130K | 61K | (11.5M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| Research & Development | 138.69M | 159.19M | 182.95M | 171.6M | 158.68M |
| Selling, General & Admin | 89.06M | 117.31M | 66.98M | 52.04M | 45.14M |
| Operating Expenses | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M |
| Depreciation & Amortization | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M |
| EBITDA | (236.6M) | (165.1M) | (214.38M) | (200.64M) | (262.91M) |
| EBITDA Margin | -2221.5% | -195.0% | -164909.2% | -328923.0% | -730302.8% |
| Operating Income | (214.78M) | (187.06M) | (247.01M) | (358.76M) | (203.77M) |
| Operating Margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| Interest Income | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (35.44M) | 3.94M | 12.38M | 15.76M | (70.67M) |
| Income Before Tax | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Pre-Tax Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Net Margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |
| EPS (Basic) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| EPS (Diluted) | (1.03) | (0.74) | (0.93) | (1.31) | (16.06) |
| 12.14M | 12.35M | 12.55M | 13.07M | 17.09M | |
| 12.14M | 12.35M | 12.55M | 13.07M | 17.09M |
LYEL Earnings Waterfall · TTM
NASDAQ:LYEL · Revenue to Net Income
Key Ratios
Analysis
$31.0K of revenue converted into -$246.4M of net income for the selected period. Gross margin is -29050.0% and net margin is -1086389.2%, showing how much revenue survives after costs and taxes. EPS is $-12.74, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3 | S-3 filing | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 |
How much revenue does LYEL generate?
Lyell Immunopharma, Inc. (LYEL) reported $36,000.00 of revenue in fiscal 2025.
Is LYEL profitable?
Lyell Immunopharma, Inc. (LYEL) reported -$274.45M of net income, with a net margin of -762355.6%.
Continue the stock analysis
Jump to another research area for this company.